Valuation: Elicera Therapeutics AB

Market Cap 167M 17.55M 15.19M 14.2M 12.98M 24.45M 1.67B 24.84M 65.34M 837M 65.89M 64.45M 2.79B P/E 2026 *
-5.8x
P/E 2027 * -4.09x
Enterprise Value 156M 16.48M 14.27M 13.34M 12.19M 22.97M 1.57B 23.33M 61.37M 786M 61.89M 60.54M 2.62B EV / Sales 2026 *
4.24x
EV / Sales 2027 * -
Free-Float
38.38%
Yield 2026 *
-
Yield 2027 * -
1 day-1.38%
1 week+4.39%
Current month+4.39%
1 month-11.84%
3 months-23.23%
6 months-51.08%
Current year-52.20%
1 week 2.3
Extreme 2.3
2.54
1 month 2.24
Extreme 2.245
2.76
Current year 2.24
Extreme 2.245
7
1 year 2.24
Extreme 2.245
8.43
3 years 0.85
Extreme 0.852
8.43
5 years 0.85
Extreme 0.852
8.8
10 years 0.85
Extreme 0.852
9
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 41 2026-05-12
Chief Executive Officer 45 2019-12-31
Director of Finance/CFO 70 2020-12-31
Director TitleAgeSince
Chairman 70 2019-12-31
Director/Board Member 65 2019-12-31
Chairman 65 2026-06-24
Date Insider Type Main position Quantity % Market Cap.
6/16/21 Free

Director

12,500 -
6/16/21 Free

Director

12,500 -
6/13/21 Free

Director

6,500 -
Change 5-day change 1-year change 3-year change Capi.($)
-1.38%+4.39%-59.23%-10.89% 17.82M
+3.90%+8.11%+90.85%+132.54% 1,057B
+0.99%+2.04%+49.36%+50.79% 625B
+0.78%-0.31%+23.01%+61.35% 435B
+1.58%+5.51%+51.42%+40.47% 363B
+0.65%+0.16%+34.81%+39.85% 296B
+0.79%-5.08%+9.78%+7.23% 249B
+1.52%+8.73%+44.49%+57.19% 222B
+0.34%-0.11%-5.23%-51.54% 209B
-0.11%+1.55%+10.55%+66.48% 165B
Average +0.52%+3.40%+24.98%+39.35% 362.08B
Weighted average by Cap. +1.04%+3.98%+49.38%+66.21%

Financials

2026 *2027 *
Net sales 36.87M 3.89M 3.36M 3.14M 2.87M 5.41M 371M 5.5M 14.47M 185M 14.59M 14.27M 617M -
Net income -25M -2.63M -2.28M -2.13M -1.95M -3.67M -251M -3.73M -9.81M -126M -9.89M -9.68M -419M -41M -4.32M -3.74M -3.5M -3.2M -6.02M -412M -6.12M -16.09M -206M -16.22M -15.87M -687M
Net Debt -10.1M -1.06M -921K -861K -787K -1.48M -102M -1.51M -3.96M -50.79M -4M -3.91M -169M 27.7M 2.92M 2.53M 2.36M 2.16M 4.07M 278M 4.13M 10.87M 139M 10.96M 10.72M 464M
Logo Elicera Therapeutics AB
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company. The Company is developing next-generation cell and gene therapies for immune-based treatment of cancer. The company is developing four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell treatments. Elicera also has a fully developed platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune strengthening in treatment in the said field. Elicera has two projects in each field: ELC-100 is an oncolytic virus, also called AdVince, that is in a clinical phase I/II trial, sponsored by Uppsala University, in the treatment of neuroendocrine tumors and ELC-301 is a CAR T-cell therapy in the treatment of B-cell lymphoma, which has been granted support from the Swedish Cancer Society for the planning and implementation of a clinical phase I/II CAR T-cell study.
Employees
3
Date Price Change Volume
26-08-10 SEK 2.495 -1.38% 186,672
26-08-07 SEK 2.530 +6.08% 528,995
26-08-06 SEK 2.385 +2.36% 144,265
26-08-05 SEK 2.330 -0.85% 103,573
26-08-04 SEK 2.350 +0.86% 134,313
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ELIC Stock